These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26121676)

  • 21. Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial.
    Nilsson M; Olafsdottir H; Alexandersson von Döbeln G; Villegas F; Gagliardi G; Hellström M; Wang QL; Johansson H; Gebski V; Hedberg J; Klevebro F; Markar S; Smyth E; Lagergren P; Al-Haidari G; Rekstad LC; Aahlin EK; Wallner B; Edholm D; Johansson J; Szabo E; Reynolds JV; Pramesh CS; Mummudi N; Joshi A; Ferri L; Wong RK; O'Callaghan C; Lukovic J; Chan KK; Leong T; Barbour A; Smithers M; Li Y; Kang X; Kong FM; Chao YK; Crosby T; Bruns C; van Laarhoven H; van Berge Henegouwen M; van Hillegersberg R; Rosati R; Piessen G; de Manzoni G; Lordick F
    Front Oncol; 2022; 12():917961. PubMed ID: 35912196
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accuracy of
    Valkema MJ; Noordman BJ; Wijnhoven BPL; Spaander MCW; Biermann K; Lagarde SM; Bennink RJ; Schreurs WMJ; Roef MJ; Hobbelink MGG; Janssen MJR; Graven LH; van Lanschot JJB; Valkema R
    J Nucl Med; 2019 Nov; 60(11):1553-1559. PubMed ID: 30877177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer.
    van der Wilk BJ; Eyck BM; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB
    Dig Surg; 2019; 36(6):462-469. PubMed ID: 30227434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability of clinical nodal status regarding response to neoadjuvant chemoradiotherapy compared with surgery alone and prognosis in esophageal cancer patients.
    Dijksterhuis WPM; Hulshoff JB; van Dullemen HM; Kats-Ugurlu G; Burgerhof JGM; Korteweg T; Mul VEM; Hospers GAP; Plukker JTM
    Acta Oncol; 2019 Nov; 58(11):1640-1647. PubMed ID: 31397195
    [No Abstract]   [Full Text] [Related]  

  • 25. Predictive value of endoscopic esophageal findings for residual esophageal cancer after neoadjuvant chemoradiotherapy.
    van der Bogt RD; van der Wilk BJ; Nikkessen S; Krishnadath KK; Schoon EJ; Oostenbrug LE; Siersema PD; Vleggaar FP; Doukas M; van Lanschot JJB; Spaander MCW
    Endoscopy; 2021 Nov; 53(11):1098-1104. PubMed ID: 33652496
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy.
    Taylor Ripley R; Surman DR; Diggs LP; Trepel JB; Lee MJ; Ryan J; Davis JL; Steinberg SM; Hernandez JM; Hoang C; Kenney CM; Bond CD; Kunst TF; Letai A; Schrump DS
    BMC Gastroenterol; 2018 Jun; 18(1):94. PubMed ID: 29933761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency of surgical resection after starting neoadjuvant chemoradiotherapy in patients with esophageal cancer: A population-based cohort study.
    Borggreve AS; van Rossum PSN; Mook S; Haj Mohammad N; van Hillegersberg R; Ruurda JP
    Eur J Surg Oncol; 2019 Oct; 45(10):1919-1925. PubMed ID: 30975447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of circulating tumour DNA after neoadjuvant chemoradiotherapy in patients with locally advanced oesophageal cancer.
    Eyck BM; Jansen MP; Noordman BJ; Atmodimedjo PN; van der Wilk BJ; Martens JW; Helmijr JA; Beaufort CM; Mostert B; Doukas M; Wijnhoven BP; Lagarde SM; van Lanschot JJB; Dinjens WN
    J Pathol; 2023 Jan; 259(1):35-45. PubMed ID: 36196486
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increasing the interval between neoadjuvant chemoradiotherapy and surgery in esophageal cancer: a meta-analysis of published studies.
    Lin G; Han SY; Xu YP; Mao WM
    Dis Esophagus; 2016 Nov; 29(8):1107-1114. PubMed ID: 26542065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
    Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
    Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial.
    Nilsson K; Klevebro F; Sunde B; Rouvelas I; Lindblad M; Szabo E; Halldestam I; Smedh U; Wallner B; Johansson J; Johnsen G; Aahlin EK; Johannessen HO; Alexandersson von Döbeln G; Hjortland GO; Wang N; Shang Y; Borg D; Quaas A; Bartella I; Bruns C; Schröder W; Nilsson M
    Ann Oncol; 2023 Nov; 34(11):1015-1024. PubMed ID: 37657554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.
    Shapiro J; van Lanschot JJB; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch ORC; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Bilgen EJS; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A;
    Lancet Oncol; 2015 Sep; 16(9):1090-1098. PubMed ID: 26254683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neoadjuvant nimotuzumab plus chemoradiotherapy compared to neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma.
    Chen Y; Wu X; Hao D; Cheng X; Zhang L; Zhang Y; Ke S; Shi W; He C
    Oncotarget; 2019 Jun; 10(40):4069-4078. PubMed ID: 31258850
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial.
    Noordman BJ; Verdam MGE; Lagarde SM; Shapiro J; Hulshof MCCM; van Berge Henegouwen MI; Wijnhoven BPL; Nieuwenhuijzen GAP; Bonenkamp JJ; Cuesta MA; Plukker JTM; Spillenaar Bilgen EJ; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB;
    Ann Oncol; 2018 Feb; 29(2):445-451. PubMed ID: 29126244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 18F-FDG PET-CT after Neoadjuvant Chemoradiotherapy in Esophageal Cancer Patients to Optimize Surgical Decision Making.
    Anderegg MC; de Groof EJ; Gisbertz SS; Bennink RJ; Lagarde SM; Klinkenbijl JH; Dijkgraaf MG; Bergman JJ; Hulshof MC; van Laarhoven HW; van Berge Henegouwen MI
    PLoS One; 2015; 10(11):e0133690. PubMed ID: 26529313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An analysis of factors affecting the accuracy of endoscopic biopsy after neoadjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma.
    Chao YK; Wen YW; Chang HK; Tseng CK; Liu YH
    Eur J Surg Oncol; 2017 Dec; 43(12):2366-2373. PubMed ID: 29070435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial.
    Noordman BJ; Verdam MGE; Lagarde SM; Hulshof MCCM; van Hagen P; van Berge Henegouwen MI; Wijnhoven BPL; van Laarhoven HWM; Nieuwenhuijzen GAP; Hospers GAP; Bonenkamp JJ; Cuesta MA; Blaisse RJB; Busch OR; Ten Kate FJW; Creemers GM; Punt CJA; Plukker JTM; Verheul HMW; Spillenaar Bilgen EJ; van Dekken H; van der Sangen MJC; Rozema T; Biermann K; Beukema JC; Piet AHM; van Rij CM; Reinders JG; Tilanus HW; Steyerberg EW; van der Gaast A; Sprangers MAG; van Lanschot JJB
    J Clin Oncol; 2018 Jan; 36(3):268-275. PubMed ID: 29161204
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of Life During and After Completion of Neoadjuvant Chemoradiotherapy for Esophageal and Junctional Cancer.
    Noordman BJ; Verdam MGE; Onstenk B; Heisterkamp J; Jansen WJBM; Martijnse IS; Lagarde SM; Wijnhoven BPL; Acosta CMM; van der Gaast A; Sprangers MAG; van Lanschot JJB
    Ann Surg Oncol; 2019 Dec; 26(13):4765-4772. PubMed ID: 31620943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
    Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
    J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Moderately differentiated esophageal squamous cell carcinoma has a poor prognosis after neoadjuvant chemoradiotherapy.
    He W; Mao T; Yan J; Leng X; Deng X; Xie Q; Peng L; Liao Q; Scarpa M; Han Y
    Ann Transl Med; 2021 Apr; 9(8):706. PubMed ID: 33987404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.